Cognitive Reserve in Parkinson's Disease without Dementia: β-Amyloid and Metabolic Assessment

Mov Disord Clin Pract. 2024 Mar;11(3):282-288. doi: 10.1002/mdc3.13967. Epub 2024 Jan 23.

Abstract

Background: Cognitive reserve (CR) is the mismatch between preserved cognition and neuropathological damage. Amyloidopathy in Parkinson's disease (PD) could be associated with faster progression to dementia, but the putative protective effect of CR is unknown.

Objectives: To evaluate the effect of CR on β-amyloid burden and brain metabolism in non-demented PD subjects.

Methods: Participants with PD (n = 53) underwent a clinical evaluation, [18 F]-fluorodeoxyglucose and [18 F]-flutemetamol positron emission tomography magnetic resonances, and were classified according to CR. The metabolic pattern of 16 controls was compared to PD subjects.

Results: The PD subjects showed hypometabolism mainly in the bilateral posterior cortex. Superior-CR subjects (n = 22) exhibited better cognitive performance, increased amyloid burden, and higher metabolism in several right hemisphere areas compared to low-medium-CR subjects (n = 31).

Conclusions: Higher CR in non-demented PD is associated with better cognitive performance, which might reduce vulnerability to the effect of β-amyloid. Whether superior CR leads to protection against metabolic deterioration, and predominantly right hemisphere involvement, deserves further exploration.

Keywords: Parkinson's disease; amyloid; cognition; cognitive reserve; metabolism.

MeSH terms

  • Amyloid beta-Peptides / metabolism
  • Cognition
  • Cognitive Reserve*
  • Dementia* / complications
  • Humans
  • Parkinson Disease* / complications
  • Tomography, X-Ray Computed

Substances

  • Amyloid beta-Peptides

Grants and funding